Company intelligence / Profile preview

Inno DMC

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

YN001, a targeted therapy for atherosclerosis using active targeting delivery system, has received IND approval from US FDA and China NMPA, marking the world's first cardiovascular targeted drug to enter clinical trials.[1][3]

Therapeutic areas: OncologyCardiovascular
Modalities: Nanoparticle
Industry: Biotech

Partnerships

Beijing Anzhen Hospital

Beyond the preview

Go deeper on Inno DMC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inno DMC.

Explore the full profile